➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 013422

Email this page to a colleague

« Back to Dashboard

NDA 013422 describes MAXIDEX, which is a drug marketed by Alcon and Novartis and is included in two NDAs. It is available from one supplier. Additional details are available on the MAXIDEX profile page.

The generic ingredient in MAXIDEX is dexamethasone. There are thirty-nine drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.
Summary for 013422
Formulation / Manufacturing:see details
Pharmacology for NDA: 013422
Medical Subject Heading (MeSH) Categories for 013422
Suppliers and Packaging for NDA: 013422
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAXIDEX dexamethasone SUSPENSION/DROPS;OPHTHALMIC 013422 NDA Alcon Laboratories, Inc. 0998-0615 0998-0615-05 5 mL in 1 BOTTLE, PLASTIC (0998-0615-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.1%
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.